H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst commented: "On February 24, Beam reported 4Q25 and full-year 2025 results and reiterated a catalyst-rich 2026 across its liver-targeted genetic disease and hematology franchises (link to deck). Highlights: (1) unveiled BEAM-304, a new gene editing program in phenylketonuria (PKU) with an investigational new drug (IND) filing anticipated in 2026; (2) updated data from BEAM-302 in alpha-1 antitrypsin deficiency (AATD) remains on-track for 1Q26 along with details on an FDA-guided potential accelerated pivotal path; (3) biologics license application (BLA) filing for risto-cel in severe sickle cell disease (SCD) remains on-track for year-end 2026; (4) announced a $500 million senior secured, long-term non-dilutive facility with Sixth Street intended to bridge the transition to potential commercial launch of risto-cel; and (5) Pfizer has opted in to an exclusive worldwide license for a liver-targeted development candidate leveraging Beam’s liver-targeting lipid nanoparticle (LNP), providing additional external validation of its platform. Beam ended 2025 with $1.25 billion in cash, cash equivalents, and marketable securities, and with the anticipated minimum $200 million draw from Sixth Street, now guides cash runway into mid-2029. We reiterate our Buy rating and $80 price target on BEAM based on growing clinical and financial momentum toward multiple key value-creating catalysts in the next 12 to 18 months."

For an analyst ratings summary and ratings history on Beam Therapeutics Inc click here. For more ratings news on Beam Therapeutics Inc click here.

Shares of Beam Therapeutics Inc closed at $28.69 yesterday.

You May Also Be Interested In

• Morgan Stanley Starts Sampo Oyj (SAMPO:FH) (SAXPY) at Equalweight
• Jefferies Downgrades Pattern Group Inc (PTRN) to Hold
• Morgan Stanley Starts Gjensidige Forsikring ASA (GJF:NO) (GJNSY) at Underweight